Therapeutic Effects of Kinesiotape in the Management of Gonarthrosis

August 12, 2025 updated by: Burcu AKKURT, Fenerbahce University

Therapeutic Effects of Kinesiotape in the Management of Gonarthrosis: A Randomized Controlled Approach

This randomized controlled trial evaluated the effectiveness of kinesiotaping in addition to exercise for patients with knee osteoarthritis (gonarthrosis). Thirty-eight participants aged 45 to 65 were randomly assigned to two groups: one group performed a structured home exercise program three times weekly for 6 weeks, while the other group performed the same program and also received kinesiotaping once weekly. Outcomes included pain, stiffness, balance, and quality of life. Both groups demonstrated significant improvement; however, the kinesiotaping plus exercise group showed greater gains in pain reduction, mobility, and daily activities. These findings suggest that kinesiotaping combined with exercise may provide superior benefits compared with exercise alone in individuals with knee osteoarthritis.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
38

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • having a diagnosis of primary gonarthrosis according to ACR classification criteria,
  • being between 45 and 65 years of age,
  • having a radiological diagnosis of gonarthrosis between Kellgren-Lawrence stage 1-3 ,
  • signing the informed consent

Exclusion Criteria:

  • presence of a neurological disorder affecting muscle strength or balance,
  • history of any surgical operation on the knee, hip or spine,
  • physiotherapy or injections for the knee within the previous year,
  • presence of systemic conditions such as diabetes mellitus, vertigo, visual problems,
  • history of severe trauma within the previous year

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental (Kinesiotape+home exercise)
The taping procedure was repeated once a week, starting from the first week, for a total of 6 sessions. Mechanical correction technique and Ligament/Tendon correction technique, as kinesiotape application, were performed. ). A 6-week home exercise program was given to both the taping and control groups, three sessions per week. An individualized home exercise program was planned, considering EULAR and ACR recommendations. Each participant was given a structured home exercise program for approximately 30 minutes per day, at least 3 days a week. The program included moderate-intensity aerobic exercises (e.g., walking) and muscle-strengthening exercises targeting the quadriceps and hamstring muscles, along with flexibility and balance exercises. ).
Other: Kinesiotape + home exercise
Kinesiotaping will be applied to the knee once weekly for 6 weeks. In addition, participants will perform a structured home exercise program three times per week, including strengthening, stretching, and balance exercises.
Active Comparator: control (home exercise )
A 6-week home exercise program was given to both the taping and control groups, three sessions per week. An individualized home exercise program was planned, considering EULAR and ACR recommendations. Each participant was given a structured home exercise program for approximately 30 minutes per day, at least 3 days a week. The program included moderate-intensity aerobic exercises (e.g., walking) and muscle-strengthening exercises targeting the quadriceps and hamstring muscles, along with flexibility and balance exercises.
Other: Home exercise
In addition, participants will perform a structured home exercise program three times per week, including strengthening, stretching, and balance exercises.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Time Frame: From enrollment to the end of treatment at 6 weeks
WOMAC consists of 24 questions in total (pain 5, joint stiffness 2, functional status 17). Each question was scored on a scale of 1-5. A high score indicates poor health, while a low score indicates good health.
From enrollment to the end of treatment at 6 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Visual Analogue Scale (VAS)
Time Frame: From enrollment to the end of treatment at 6 weeks
VAS, which ranges from 0 to 10, is used to assess pain levels. A score of 0 represents no pain, while 10 indicates the most severe, unbearable pain. Participants were instructed to indicate their perceived pain level by marking a 10 cm straight line, and the corresponding value was recorded in centimeters.
From enrollment to the end of treatment at 6 weeks
Berg Balance Scale (BBS)
Time Frame: From enrollment to he end of treatment at 6 weeks.
BBS is a test consisting of 14 items used to evaluate the functional balance of individuals. The application time is approximately 15-20 minutes, and the following materials are needed: a ruler, a stopwatch, a chair, a step, and an area suitable for 360-degree rotation. Each item is evaluated on a scale of 0-4 points based on the individual's ability to perform the given task independently and correctly. The total score is 56. A score between 0-20 indicates severe balance impairment, between 21-40 indicates acceptable balance, and between 41-56 indicates good balance.
From enrollment to he end of treatment at 6 weeks.
Short Form (SF-36)
Time Frame: From enrollment to the end of treatment at 6 weeks
The SF-36 questionnaire was developed to assess quality of life. A total of 8 sub-parameters, including pain, social functioning, energy/vitality, emotional role difficulties, physical role difficulties, physical functioning, general health perception, and mental health, are examined
From enrollment to the end of treatment at 6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Fenerbahce University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 1, 2015

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2016

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2016

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 5, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 12, 2025

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 15, 2025

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 15, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 12, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2015-17/04

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared due to concerns regarding patient confidentiality and data privacy

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gonarthrosis

Clinical Trials on Kinesiotape + home exercise

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings